標(biāo)題: Titlebook: Drug-Coated Balloons; Applications in Inte Bernardo Cortese Book 2019 Springer Nature Switzerland AG 2019 drug-eluting balloon.angioplasty [打印本頁] 作者: 詞源法 時間: 2025-3-21 19:25
書目名稱Drug-Coated Balloons影響因子(影響力)
書目名稱Drug-Coated Balloons影響因子(影響力)學(xué)科排名
書目名稱Drug-Coated Balloons網(wǎng)絡(luò)公開度
書目名稱Drug-Coated Balloons網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Drug-Coated Balloons被引頻次
書目名稱Drug-Coated Balloons被引頻次學(xué)科排名
書目名稱Drug-Coated Balloons年度引用
書目名稱Drug-Coated Balloons年度引用學(xué)科排名
書目名稱Drug-Coated Balloons讀者反饋
書目名稱Drug-Coated Balloons讀者反饋學(xué)科排名
作者: 古代 時間: 2025-3-21 20:39
Springer Nature Switzerland AG 2019作者: 圖表證明 時間: 2025-3-22 02:31 作者: canonical 時間: 2025-3-22 05:04 作者: 小鹿 時間: 2025-3-22 12:25
https://doi.org/10.1007/978-1-4302-1089-4disease treatment with three Palmaz-Schatz stents (not yet approved in the USA by the FDA) [1]; the second one was a recanalization of a CTO with a laser wire in a patient included in the TOTAL trial [2]; the third one was a drug-eluting balloon treatment (the Dispatch balloon) post balloon angioplasty [3].作者: 使增至最大 時間: 2025-3-22 13:00 作者: 使增至最大 時間: 2025-3-22 19:24 作者: 別炫耀 時間: 2025-3-23 01:13 作者: 河流 時間: 2025-3-23 04:12
https://doi.org/10.1007/978-1-4302-1089-4disease treatment with three Palmaz-Schatz stents (not yet approved in the USA by the FDA) [1]; the second one was a recanalization of a CTO with a laser wire in a patient included in the TOTAL trial [2]; the third one was a drug-eluting balloon treatment (the Dispatch balloon) post balloon angiopla作者: Schlemms-Canal 時間: 2025-3-23 07:52 作者: 杠桿支點 時間: 2025-3-23 09:43
https://doi.org/10.1007/978-1-4302-1089-4ery disease. Although the DCB technology is still in its infancy, it has already demonstrated its beneficial effects in patients with coronary in-stent restenosis (ISR) [1] and peripheral artery disease [2]. Hallmark of the DCB is the local delivery of an antirestenotic drug into the vessel wall dur作者: 執(zhí)拗 時間: 2025-3-23 14:38
https://doi.org/10.1007/978-1-4302-1089-4 The most striking revolution in the percutaneous treatment of coronary artery disease has undoubtedly been the introduction of the drug-eluting stent (DES). Drug-eluting stents made a revolution in interventional cardiology, not only by improving the mechanical limitations of balloon angioplasty bu作者: omnibus 時間: 2025-3-23 21:17 作者: 使饑餓 時間: 2025-3-23 23:38
https://doi.org/10.1007/978-1-4302-1089-4xel and sirolimus are two choices in DCBs and both drugs have their own advantages. Use of sirolimus on DCBs is not yet well known but may replace use of of paclitaxel in the coming years when key design criteria are compared. From the scientific perspective, researchers developing DCB in the labora作者: arrhythmic 時間: 2025-3-24 02:36
https://doi.org/10.1007/978-1-4302-1089-4ist and include concerns about stent thrombosis, increased bleeding risk due to prolonged dual antiplatelet therapy, and limited access for future coronary bypass grafting. Not only these limitations, but also the increase of complex percutaneous coronary interventions as well as the establishment o作者: nascent 時間: 2025-3-24 07:20 作者: 不規(guī)則的跳動 時間: 2025-3-24 13:03
https://doi.org/10.1007/978-1-4302-1089-4estenosis caused byneointimal hyperplasia. Some of the limitations of DES include treatment of small vessel disease, issues related to the duration of dual antiplatelet therapy (DAPT), and treatment failure leading to restenosis and late or very late stent thrombosis, especially in complex lesions s作者: 樹木心 時間: 2025-3-24 17:01 作者: 新手 時間: 2025-3-24 19:24
https://doi.org/10.1007/978-1-4302-1111-2, abrupt vessel closure, and coronary dissection. Regardless of the angiographic and morphological classification {Waller:1992tr}, the incidence of coronary dissection after PTCA has been reported ranging from 4% to 45% {Dorros:1983wf}{GuiterasVal:1987wy}, while autoptic studies showed the presence 作者: 無法治愈 時間: 2025-3-25 02:58
Writing C Modules with Inline::C,s associated with a plain old balloon angioplasty (POBA) for SFA, lumen renarrowing at the stented level (in-stent restenosis, ISR) represents a relevant clinical problem..Several endovascular approach have been attempted to treat ISR (i.e., POBA, debulking, use of covered stents) but, as of today, 作者: Flatus 時間: 2025-3-25 06:07
Submitting Your Module to CPAN, and quality of life. However, this disease is frequently underdiagnosed and undertreated. Revascularization improves symptoms and functional status and has potential to impact on prognosis. Surgical revascularization used to be the only available strategy, but in recent years, endovascular strategi作者: 微不足道 時間: 2025-3-25 08:41 作者: Offstage 時間: 2025-3-25 14:10
Strong, Em, and Other Phrase Elementsed in several settings and widely used both in clinical trials and in daily practice. The aim of this chapter is to evaluate the clinical performance and rationale of DCB use in “real-world” scenarios in coronary artery disease.作者: 軍械庫 時間: 2025-3-25 19:08
Strong, Em, and Other Phrase Elementsith unfavorable clinical outcomes, while data regarding the feasibility and safety of using drug-eluting stents (DES) are limited. The strategy of using DES is potentially advantageous since combining different types of antiproliferative drugs may inhibit neointimal hyperplasia more effectively when作者: 不可接觸 時間: 2025-3-25 23:25 作者: 膽大 時間: 2025-3-26 01:37
Improving Performance with Web MatrixLate lumen enlargement (LLE) is an increase of the luminal size of a coronary artery following angioplasty, compared to the immediate post intervention luminal size. We discuss the possible contributory factors here specially focusing on late lumen enlargement seen after drug coated balloon (DCB) - only angioplasty.作者: 煉油廠 時間: 2025-3-26 05:59 作者: Gratuitous 時間: 2025-3-26 10:47
History of Drug-Coated Balloons,The advent of balloon angioplasty (BA) for the treatment of coronary artery disease was performed by Andreas Grüntzig in 1977 [1] (Fig. 1.1) and represented a breakthrough in the field of cardiology: by that time, we can say that modern interventional cardiology was born.作者: 缺陷 時間: 2025-3-26 13:29 作者: 地殼 時間: 2025-3-26 19:38
Sirolimus-Coated Balloon: Insights on a New Technology for Coronary Use,Nowadays, limus-eluting stents dominate the world of drug-eluting stents (DES) and proved to be superior to paclitaxel-eluting stents in terms of efficacy and safety [1].作者: NOMAD 時間: 2025-3-26 22:19
Book 2019eripheral arterial disease. In addition to clear explanation of how DCBs works, readers will find an enlightening analysis of the mistakes and successes of the past decade and the emergence of the latest delivery systems, which combine a more deliverable device with much improved drug delivery to th作者: 大漩渦 時間: 2025-3-27 02:54
sel wall.Examines the applications of DCBs in different treaThis book provides a comprehensive, up-to-date summary of drug-coated balloon (DCB) technology and the role of DCBs in the treatment of coronary and peripheral arterial disease. In addition to clear explanation of how DCBs works, readers wi作者: 粗糙 時間: 2025-3-27 05:33 作者: 供過于求 時間: 2025-3-27 12:32 作者: wall-stress 時間: 2025-3-27 16:39 作者: 干涉 時間: 2025-3-27 21:13 作者: Mets552 時間: 2025-3-27 23:25 作者: BADGE 時間: 2025-3-28 02:38
Dissection Management with Drug-Coated Balloons,ronary dissection after PTCA has been reported ranging from 4% to 45% {Dorros:1983wf}{GuiterasVal:1987wy}, while autoptic studies showed the presence of coronary dissections in up to 80% of the cases, independently from the cause of death {Baughman:1981gb}, of patients treated with balloon angioplasty.作者: lacrimal-gland 時間: 2025-3-28 08:09
https://doi.org/10.1007/978-1-4302-1089-4ic events. In this light, the shorter dual antiplatelet therapy (DAPT) duration usually required with DCB may be an advantage because it warrants a reduced bleeding risk, especially in high-risk and compromised patients.作者: 圓錐體 時間: 2025-3-28 11:20
https://doi.org/10.1007/978-1-4302-1089-4ing very short balloon-vessel contact, without the need for implantation of permanent scaffolds. The antirestenotic drug prevents restenosis after vascular intervention through inhibition of neointimal hyperplasia [3–5] and possibly by modification of the arterial remodeling response [3, 6, 7].作者: incredulity 時間: 2025-3-28 16:54 作者: 明智的人 時間: 2025-3-28 22:36 作者: 背叛者 時間: 2025-3-29 00:15
The Use of Drug-Coated Balloons for Patients with In-Stent Restenosis,ocardial infarction, a complex scenario associated with plaque rupture and a large thrombus burden where the acute results of stent implantation may not be optimal. At last DCB have been used in selected de novo lesions providing satisfactory angiographic results obtained upon dilatation.作者: 厭倦嗎你 時間: 2025-3-29 05:46 作者: 奇怪 時間: 2025-3-29 08:46 作者: 歡呼 時間: 2025-3-29 12:29
Writing C Modules with Inline::C, the use of DCB is associated with a reduction in recurrent restenosis and target lesion revascularization (TLR) at least at 1 year after plain old balloon angioplasty (POBA). The available data strongly support the use of DCB to reduce SFA ISR recurrence.作者: right-atrium 時間: 2025-3-29 16:17
Strong, Em, and Other Phrase Elementsthough further investigations to evaluate endothelization patterns and long-term clinical outcomes are required, bailout DES implantation is a reasonable strategy to manage suboptimal DCB results, especially when treating complex lesions.作者: temperate 時間: 2025-3-29 21:09
Technical Insights on Drug-Coated Balloons,ayed vessel healing [3, 4]. Current guidelines recommend the use of prolonged double antiplatelet therapy (DAPT) following DES implantation which may become problematic in specific clinical settings where a shorter DAPT period is desired (i.e., high-bleeding-risk patients) [5].作者: 的是兄弟 時間: 2025-3-30 01:32
Potential Clinical Advantages of Drug-Coated Balloon in Specific Clinical Settings,ce for an indication of DCB angioplasty in the treatment of metallic in-stent restenosis, further clinical scenarios have been investigated for the use of DCB with promising results for some of them. Current data on clinical scenarios with potential advantages of DCB angioplasty are summarized in this chapter.作者: 過度 時間: 2025-3-30 05:04
Drug-Coated Balloon in Superficial Femoral Artery In-Stent Restenosis, the use of DCB is associated with a reduction in recurrent restenosis and target lesion revascularization (TLR) at least at 1 year after plain old balloon angioplasty (POBA). The available data strongly support the use of DCB to reduce SFA ISR recurrence.作者: Abominate 時間: 2025-3-30 11:58
Stent Use After Drug-Coated Balloons,though further investigations to evaluate endothelization patterns and long-term clinical outcomes are required, bailout DES implantation is a reasonable strategy to manage suboptimal DCB results, especially when treating complex lesions.作者: 馬具 時間: 2025-3-30 15:25 作者: avenge 時間: 2025-3-30 19:55
Local Drug Delivery to Prevent Restenosis of the Coronary and Peripheral Arteries,ing very short balloon-vessel contact, without the need for implantation of permanent scaffolds. The antirestenotic drug prevents restenosis after vascular intervention through inhibition of neointimal hyperplasia [3–5] and possibly by modification of the arterial remodeling response [3, 6, 7].作者: neuron 時間: 2025-3-30 22:50
Design Parameters for Drug-Coated Balloons II,tory need to consider certain criteria. DCB development needs to fulfill multiple criteria with regard to the drug, device, drug carrier, physicochemical properties of the drug and drug carrier, particle size and coating methodology.作者: left-ventricle 時間: 2025-3-31 03:23
,From Drug-Eluting Balloon to Drug-Coated Balloon … to Eradication of Intracoronary Metal, a New Enddisease treatment with three Palmaz-Schatz stents (not yet approved in the USA by the FDA) [1]; the second one was a recanalization of a CTO with a laser wire in a patient included in the TOTAL trial [2]; the third one was a drug-eluting balloon treatment (the Dispatch balloon) post balloon angiopla作者: Tartar 時間: 2025-3-31 05:55
Previous Mistakes with DCB Technology, and How to Prevent Them in the Future,n angioplasty covered by an antiproliferative drug. This technology allows to bring high concentration of an antiproliferative drug with rapid local delivery without the implantation of an external prosthesis like a metal stent or a scaffold, technologies associated with some late-occurring thrombot作者: 關(guān)心 時間: 2025-3-31 13:12 作者: violate 時間: 2025-3-31 14:28
Technical Insights on Drug-Coated Balloons, The most striking revolution in the percutaneous treatment of coronary artery disease has undoubtedly been the introduction of the drug-eluting stent (DES). Drug-eluting stents made a revolution in interventional cardiology, not only by improving the mechanical limitations of balloon angioplasty bu作者: 矛盾 時間: 2025-3-31 18:40
Technical Insights on Drug-Coated Balloons II,ease of the drug to treat posttreatment shortcomings. Currently paclitaxel and sirolimus are the only choices for drug-coated balloons. Preclinical study findings on paclitaxel are mixed and depend on various factors such as the drug carrier, balloon surface, drug size, coating method etc. The sirol作者: 周年紀(jì)念日 時間: 2025-4-1 00:53
Design Parameters for Drug-Coated Balloons II,xel and sirolimus are two choices in DCBs and both drugs have their own advantages. Use of sirolimus on DCBs is not yet well known but may replace use of of paclitaxel in the coming years when key design criteria are compared. From the scientific perspective, researchers developing DCB in the labora作者: Interferons 時間: 2025-4-1 03:27 作者: 執(zhí)拗 時間: 2025-4-1 09:24
The Use of Drug-Coated Balloons for Patients with In-Stent Restenosis,estenosis (ISR) [1]. Other scenarios for the use of DCB include small vessels, diffuse disease, and coronary bifurcation where the systematic implantation of a stent is not very attractive or is associated with adverse clinical and angiographic results. Information on the value of DCB in these setti作者: 性滿足 時間: 2025-4-1 11:51
Drug-Coated Balloons in Native Coronary Artery Disease,estenosis caused byneointimal hyperplasia. Some of the limitations of DES include treatment of small vessel disease, issues related to the duration of dual antiplatelet therapy (DAPT), and treatment failure leading to restenosis and late or very late stent thrombosis, especially in complex lesions s作者: 有權(quán) 時間: 2025-4-1 17:38
Drug-Eluting Balloons in Coronary Bifurcation Lesions,il and late negative remodeling and by pharmacologically inhibiting neointimal hyperplasia [1]. However complex lesions, such as bifurcation lesions, which account for 15–20% of all lesions treated percutaneously [2], remain hampered by technical difficulties, periprocedural complications, and subop
